Equity Overview
Price & Market Data
Price: $1.20
Daily Change: +$0.05 / 4.17%
Daily Range: $1.16 - $1.20
Market Cap: $133,702,968
Daily Volume: 2,534
Performance Metrics
1 Week: 1.77%
1 Month: -13.53%
3 Months: 13.86%
6 Months: -4.96%
1 Year: 26.46%
YTD: 17.04%
Company Details
Employees: 161
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.